Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythrocyte Membrane n-6/n-3 Fatty Acid Ratio Predicts Severe Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma
NCT07920250Phase 2Completed
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Nov 2024
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoints: Longitudinal change in erythrocyte membrane n-6/n-3 fatty acid ratio, Longitudinal change in erythrocyte membrane ALA level and 5 more. Started Nov 2024; status: completed.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07920250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920250.